CervoMed Inc.

CervoMed Inc. is a clinical-stage biotechnology company dedicated to developing treatments for age-related neurologic disorders. The company's mission centers on advancing therapies that target critical disease processes underlying degenerative disorders of the brain. Headquartered in Boston, Massachusetts, USA, CervoMed was co-founded by John Alam, who serves as its Chief Executive Officer.

CervoMed's primary product candidate is neflamapimod, an investigational, orally administered small molecule brain penetrant. This compound selectively inhibits the alpha isoform of p38 mitogen-activated protein kinase (p38 MAPKα), an enzyme identified as a key driver of neuroinflammation and synaptic dysfunction. The company is primarily focused on developing neflamapimod for the treatment of central nervous system (CNS) disorders, with a significant emphasis on Dementia with Lewy Bodies (DLB). Additionally, neflamapimod is being evaluated for other conditions such as frontotemporal dementia (FTD), nonfluent variant primary progressive aphasia (nfvPPA), and recovery after ischemic stroke.

CervoMed became a publicly traded company following its merger with Diffusion Pharmaceuticals Inc. in August 2023, with the combined entity retaining the name CervoMed Inc. and trading on Nasdaq under the ticker symbol "CRVO". The company has received a $21 million grant from the National Institute on Aging (NIA) to support its Phase 2b clinical study of neflamapimod in DLB. Recent developments include the presentation of initial results from a Phase 2a clinical trial of neflamapimod in nfvPPA in September 2026 and the announcement of pharmacokinetic results for a new oral tablet formulation, alongside the FDA's removal of a prior drug exposure limit. CervoMed is currently preparing for a global, pivotal Phase 3 trial in DLB, anticipated to commence in the second half of 2026.